CoChat

Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap

Pratt, Judith, Winchester, Catherine, Dawson, Neil, Morris, Brian · 2012 · Nature Reviews Drug Discovery
Cited by 183

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrd3649

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 148

  1. Lieberman. J. A. & Stroup, T. S. The NIMH-CATIE Schizophrenia Study: what did we learn? Am. J. Psychiatry. 168, 770–775 (2011). · DOI
  2. Nasrallah, H. A. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol. Psychiatry 13, 27–35 (2008). · DOI · Paper page
  3. Meltzer, H. Y. What's atypical about atypical antipsychotic drugs? Curr. Opin. Pharmacol. 4, 53–57 (2004). · DOI · Paper page
  4. Paz, R. D., Tardito, S., Atzori, M. & Tseng, K. Y. Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur. Neuropsychopharmacol. 18, 773–786 (2008). · DOI · Paper page
  5. Adams, B. W. & Moghaddam, B. Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex. Biol. Psychiatry 50, 750–757 (2001). · DOI
  6. Nudmamud-Thanoi S., Piyabhan P., Harte M. K., Cahir M. & Reynolds G. P. Deficits of neuronal glutamatergic markers in the caudate nucleus in schizophrenia. J. Neural Transm. Suppl. 72, 281–285 (2007). · DOI
  7. Harrison, P. J., Law, A. J. & Eastwood, S. L. Glutamate receptors and transporters in the hippocampus in schizophrenia. Ann. NY Acad. Sci. 1003, 94–101 (2003). · DOI · Paper page
  8. Harrison, P. J. & Eastwood, S. L. Vesicular glutamate transporter (VGLUT) gene expression provides further evidence for glutamatergic synaptic pathology in the hippocampus in schizophrenia. Schizophr. Res. 60, S62–S63 (2003). · DOI
  9. Kristiansen, L. V., Huerta, I., Beneyto, M. & Meador-Woodruff, J. H. NMDA receptors and schizophrenia. Curr. Opin. Pharmacol. 7, 48–55 (2007). · DOI · Paper page
  10. Schwartz, T. L., Sachdeva, S. & Stahl, S. M. 'Genetic data supporting the NMDA glutamate receptor hypothesis for schizophrenia'. Curr. Pharm. Des. 18, 1580–1592 (2012). · DOI
  11. Large, C. H. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? J. Psychopharmacol. 21, 283–301 (2007). · DOI · Paper page
  12. Hagan, J. J. & Jones, D. N. C. Predicting drug efficacy for cognitive deficits in schizophrenia. Schizophr. Bull. 31, 830–853 (2005). · DOI · Paper page
  13. Heekeren, K. et al. Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis. J. Psychopharmacol. 21, 312–320 (2007). · DOI · Paper page
  14. Sams-Dodd, F. Effects of dopamine agonists and antagonists on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Psychopharmacology 135, 182–193 (1998). · DOI
  15. Young, J. W., Powell, S. B., Risbrough, V., Marston, H. M. & Geyer, M. A. Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol. Ther. 122, 150–202 (2009). · DOI · Paper page
  16. Thomson, D. M., Mcvie, A., Morris, B. J. & Pratt, J. A. Dissociation of acute and chronic intermittent phencyclidine-induced performance deficits in the 5-choice serial reaction time task: influence of clozapine. Psychopharmacology 213, 681–695 (2011). · DOI
  17. Amitai, N. & Semenova, S. & Markou, A. Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. Psychopharmacology 193, 521–537 (2007). · DOI
  18. Thomsen, M. S., Hansen, H. H., Timmerman, D. B. & Mikkelsen, J. D. Cognitive improvement by activation of α7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr. Pharm. Des. 16, 323–343 (2010). · DOI · Paper page
  19. Martin, L. F., Kem, W. R. & Freedman, R. α-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology 174, 54–64 (2004). · DOI · Paper page
  20. Morein-Zamir, S., Turner, D. C. & Sahakian, B. J. A review of the effects of modafinil on cognition in schizophrenia. Schizophr. Bull. 33, 1298–1306 (2007). · DOI · Paper page
  21. Scoriels, L., Barnett, J. H., Soma, P. K., Sahakian, B. J. & Jones, P. B. Effects of modafinil on cognitive functions in first episode psychosis. Psychopharmacology 220, 249–258 (2012). · DOI
  22. Goetghebeur, P. & Dias, R. Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat — a back translational study. Psychopharmacology 202, 287–293 (2009). · DOI
  23. Pratt, J. A., Dawson, N., Winchester, C. L., Thomson, D. M. & Morris, B. J. Distinct aspects of prefrontal cortex dysfunction in schizophrenia modelled by acute and repeated PCP treatment: impact of modafinil. Schizophr. Res. 117, 509 (2010). · doi:10.1016/j.schres.2010.02.972
  24. Rodefer, J. S., Murphy, E. R. & Baxter, M. G. PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur. J. Neurosci. 21, 1070–1076 (2005). · DOI · Paper page
  25. Hatcher, P. D. et al. 5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats. Psychopharmacology 181, 253–259 (2005). · DOI
  26. Morris, B. J., Cochran, S. M. & Pratt, J. A. PCP: from pharmacology to modelling schizophrenia. Curr. Opin. Pharmacol. 5, 101–106 (2005). · DOI · Paper page
  27. Ellenbroek, B. A. & Cools, A. R. The neurodevelopment hypothesis of schizophrenia: clinical evidence and animal models. Neurosci. Res. Commun. 22, 127–136 (1998). · DOI · Paper page
  28. Hayashi-Takagi, A. & Sawa, A. Disturbed synaptic connectivity in schizophrenia: convergence of genetic risk factors during neurodevelopment. Brain Res. Bull. 83, 140–146 (2010). · DOI
  29. Charych, E. I., Liu, F., Moss, S. J. & Brandon, N. J. GABAA receptors and their associated proteins: implications in the etiology and treatment of schizophrenia and related disorders. Neuropharmacology 57, 481–495 (2009). · DOI · Paper page
  30. Kim, J. Y. et al. Interplay between DISC1 and GABA signaling regulates neurogenesis in mice and risk for schizophrenia. Cell 148, 1051–1064 (2012). · DOI · Paper page
  31. Atack, J. R. GABAA receptor α2/α3 subtype-selective modulators as potential nonsedating anxiolytics. Curr. Top. Behav. Neurosci. 2, 331–360 (2011). · DOI
  32. Tseng, K. Y., Chambers, R. A. & Lipska, B. K. The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia. Behav. Brain Res. 204, 295–305 (2009). · DOI · Paper page
  33. Becker, A., Grecksch, G., Bernstein, H. G., Hollt, V. & Bogerts, B. Social behaviour in rats lesioned with ibotenic acid in the hippocampus: quantitative and qualitative analysis. Psychopharmacology 144, 333–338 (1999). · DOI · Paper page
  34. Le Pen, G. et al. Impact of chronic antipsychotic treatments on hypersensitivity to MK-801 in a neurodevelopmental model of schizophrenia. Eur. Neuropsychopharmacol. 17, S480–S481 (2007). · doi:10.1016/s0924-977x(07)70734-4
  35. Lodge, D. J. & Grace, A. A. Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia. Behav. Brain Res. 204, 306–312 (2009). · DOI · Paper page
  36. Bitanihirwe, B. K. Y., Peleg-Raibstein, D., Mouttet, F., Feldon, J. & Meyer, U. Late prenatal immune activation in mice leads to behavioral abnormalities relevant to the negative symptoms of schizophrenia. Schizophr. Res. 117, 273–274 (2010). · doi:10.1016/j.schres.2010.02.439
  37. Ozawa, K. et al. Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol. Psychiatry 59, 546–554 (2006). · DOI · Paper page
  38. Cardno, A. G., Rijsdijk, F. V., Gottesman, I. I. & McGuffin, P. Heritability estimates for psychotic symptom dimensions in twins with psychotic disorders. Am. J. Med. Genet. B Neuropsychiatr. Genet. 156B, 89–98 (2011).
  39. Mitchell, K. J. What is complex about complex disorders? Genome Biol. 13, 237 (2012). · DOI · Paper page
  40. Ayhan, Y., Sawa, A., Ross, C. A. & Pletnikov, M. V. Animal models of gene–environment interactions in schizophrenia. Behav. Brain Res. 204, 274–281 (2009). · DOI · Paper page
  41. Arguello, P. A. & Gogos, J. A. Genetic and cognitive windows into circuit mechanisms of psychiatric disease. Trends Neurosci. 35, 3–13 (2012). · DOI
  42. Allen, N. C. et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nature Genet. 40, 827–834 (2008). · DOI · Paper page
  43. Swerdlow, N. R., Geyer, M. A. & Braff, D. L. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology 156, 194–215 (2001). · DOI · Paper page
  44. van den Buuse, M. Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr. Bull. 36, 246–270 (2010). · DOI · Paper page
  45. Fitzgerald, P. J. et al. Does gene deletion of AMPA GluA1 phenocopy features of schizoaffective disorder? Neurobiol. Dis. 40, 608–621 (2010). · DOI · Paper page
  46. Bannerman, D. M. et al. NMDA receptor subunit NR2A is required for rapidly acquired spatial working memory but not incremental spatial reference memory. J. Neurosci. 28, 3623–3630 (2008). · DOI · Paper page
  47. Inta, D., Monyer, H., Sprengel, R., Meyer-Lindenberg, A. & Gass, P. Mice with genetically altered glutamate receptors as models of schizophrenia: a comprehensive review. Neurosci. Biobehav. Rev. 34, 285–294 (2010). · DOI
  48. Lipina, T. V. et al. Genetic and pharmacological evidence for schizophrenia-related Disc1 interaction with GSK-3. Synapse 65, 234–248 (2011). · DOI · Paper page
  49. Boulay, D. et al. Comparative phenotype in behavioral models related to schizophrenia: Disc1 (L100P) mutant, NMDA Nr1neo−/− hypomorphic and DAT−/− mice. Program No. 766.1 2010 Neuroscience Meeting Planner (San Diego, California; Society for Neuroscience, 2010).
  50. Shoji, H. et al. Comprehensive behavioral analysis of ENU-induced Disc1-Q131L and -L100P mutant mice. BMC Res. Notes 5, 108 (2012). · DOI
  51. Shen, S. et al. Schizophrenia-related neural and behavioral phenotypes in transgenic mice expressing truncated Disc1. J. Neurosci. 28, 10893–10904 (2008). · DOI · Paper page
  52. Kvajo, M. et al. Altered axonal targeting and short-term plasticity in the hippocampus of Disc1 mutant mice. Proc. Natl Acad. Sci. USA 108, E1349–E1358 (2011). · DOI · Paper page
  53. Gainetdinov, R. R. Dopamine transporter mutant mice in experimental neuropharmacology. Naunyn Schmiedebergs Arch. Pharmacol. 377, 301–313 (2008). · DOI
  54. Wen, L. et al. Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons. Proc. Natl Acad. Sci. USA 107, 1211–1216 (2010). · DOI · Paper page
  55. Simpson, E. H. et al. Pharmacologic rescue of motivational deficit in an animal model of the negative symptoms of schizophrenia. Biol. Psychiatry 69, 928–935 (2011). · DOI · Paper page
  56. Pearlson, G. D. & Calhoun, V. D. Convergent approaches for defining functional imaging endophenotypes in schizophrenia. Front. Hum. Neurosci. 3, 37 (2009). · DOI · Paper page
  57. Braff, D. L., Freedman, R., Schork, N. J. & Gottesman, I. I. Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophr. Bull. 33, 21–32 (2007). · DOI · Paper page
  58. Callicott, J. H. et al. Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down. Am. J. Psychiatry 160, 2209–2215 (2003). · DOI · Paper page
  59. Potkin, S. G. et al. Working memory and DLPFC inefficiency in schizophrenia: the FBIRN study. Schizophr. Bull. 35, 19–31 (2009). · DOI · Paper page
  60. McIntosh, A. R., Nyberg, L., Bookstein, F. L. & Tulving, E. Differential functional connectivity of prefrontal and medial temporal cortices during episodic memory retrieval. Hum. Brain Mapp. 5, 323–327 (1997). · DOI · Paper page
  61. Friston, K. J. & Frith, C. D. Schizophrenia: a disconnection syndrome. Clin. Neurosci. 3, 89–97 (1995).
  62. Meyer-Lindenberg, A. et al. Evidence for abnormal cortical functional connectivity during working memory in schizophrenia. Am. J. Psychiatry 158, 1809–1817 (2001). · DOI · Paper page
  63. Mcintosh, A. R. & Gonzalezlima, F. Structural modeling of functional neural pathways mapped with 2-deoxyglucose: effects of acoustic startle habituation on the auditory-system. Brain Res. 547, 295–302 (1991). · DOI · Paper page
  64. Dawson, N. et al. Modafinil reverses phencyclidine-induced deficits in cognitive flexibility, cerebral metabolism, and functional brain connectivity. Schizophr. Bull. 38, 457–474 (2012). · DOI · Paper page
  65. Cochran, S. M. et al. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 28, 265–275 (2003). · DOI · Paper page
  66. Hunter, M., Ganesan, V. S. & Spence, S. A. Effects of modafinil on prefrontal function and voluntary behaviour in chronic schizophrenia. Schizophr. Bull. 31, 511–512 (2005).
  67. Spence, S. A., Green, R. D., Wilkinson, I. D. & Hunter, M. D. Modafinil modulates anterior cingulate function in chronic schizophrenia. Br. J. Psychiatry 187, 55–61 (2005). · DOI · Paper page
  68. Minzenberg, M. J. et al. Response to comment on “modafinil shifts human locus coeruleus to low-tonic, high-phasic activity during functional MRI”. Science 328, 309 (2010). · DOI
  69. Pratt, J. A., Winchester, C., Egerton, A., Cochran, S. M. & Morris, B. J. Modelling prefrontal cortex deficits in schizophrenia: implications for treatment. Br. J. Pharmacol. 153, S465–S470 (2008). · DOI · Paper page
  70. Egerton, A. et al. Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats. Psychopharmacology 198, 37–49 (2008). · DOI
  71. Bullmore, E. et al. Hierarchical organization of human cortical networks in health and schizophrenia. J. Neurosci. 28, 9239–9248 (2008). · DOI · Paper page
  72. Micheloyannis, S. et al. Small-world networks and disturbed functional connectivity in schizophrenia. Schizophr. Res. 87, 60–66 (2006). · DOI · Paper page
  73. Liu, Y. et al. Disrupted small-world networks in schizophrenia. Brain 131, 945–961 (2008). · DOI · Paper page
  74. Dawson, N., Higham, D., Pratt, J. & Morris, B. Alterations in functional brain network structure induced by subchronic phencyclidine (PCP) treatment parallel those seen in schizophrenia. Schizophr. Res. 117, 234–235 (2010). · doi:10.1016/j.schres.2010.02.349
  75. Sohal, V. S. Insights into cortical oscillations arising from optogenetic studies. Biol. Psychiatry 71, 1039–1045 (2012). · DOI · Paper page
  76. Wulff, P. et al. Hippocampal theta rhythm and its coupling with gamma oscillations require fast inhibition onto parvalbumin-positive interneurons. Proc. Natl Acad. Sci. USA 106, 3561–3566 (2009). · DOI · Paper page
  77. Uhlhaas, P. J. et al. Impaired γ-band synchrony during dysfunctional gestalt perception in schizophrenia. Biol. Psychiatry 59, 5S (2006).
  78. Jaaro-Peled, H., Ayhan, Y., Pletnikov, M. V. & Sawa, A. Review of pathological hallmarks of schizophrenia: comparison of genetic models with patients and nongenetic models. Schizophr. Bull. 36, 301–313 (2010). · DOI · Paper page
  79. Lawrie, S. M., Hall, J., McIntosh, A. M., Cunningham-Owens, D. G. & Johnstone, E. C. Neuroimaging and molecular genetics of schizophrenia: pathophysiological advances and therapeutic potential. Br. J. Pharmacol. 153, S120–S124 (2008). · DOI
  80. Weinberger, D. et al. Plenary session — on the matter of neuroimaging in the context of schizophrenia genetics. Schizophr. Res. 117, 109–110 (2010). · doi:10.1016/j.schres.2010.02.023
  81. Egan, M. F. et al. Effect of COMT Val(108/158) Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl Acad. Sci. USA 98, 6917–6922 (2001). · DOI · Paper page
  82. Egan, M. F. et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc. Natl Acad. Sci. USA 101, 12604–12609 (2004). · DOI · Paper page
  83. Weinberger, D. R. et al. A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia. Nature Med. 15, 509–518 (2009). · DOI · Paper page
  84. Callicott, J. et al. Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Neuropsychopharmacology 101, 12604–12609 (2004).
  85. Straub, R. E. et al. Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression. Mol. Psychiatry 12, 854–869 (2007). · DOI · Paper page
  86. McIntosh, A. M. et al. The effects of a neuregulin 1 variant on white matter density and integrity. Mol. Psychiatry 13, 1054–1059 (2008). · DOI · Paper page
  87. Esslinger, C. et al. Cognitive state and connectivity effects of the genome-wide significant psychosis variant in ZNF804A. Neuroimage 54, 2514–2523 (2011). · DOI
  88. Potkin, S. G. et al. A genome-wide association study of schizophrenia using brain activation as a quantitative phenotype. Schizophr. Bull. 35, 96–108 (2009). · DOI · Paper page
  89. Weinberger, D. R. et al. No effect of a common allelic variant in the reelin gene on intermediate phenotype measures of brain structure, brain function, and gene expression. Biol. Psychiatry 68, 105–107 (2010). · DOI
  90. Bramon, E. et al. Psychosis biological markers and their genetic influences. Schizophr. Res. 117, 217 (2010). · doi:10.1016/j.schres.2010.02.308
  91. Seeman, P. Dopamine D2 receptors as treatment targets in schizophrenia. Clin. Schizophr. Relat. Psychoses 4, 56–73 (2010). · DOI · Paper page
  92. Nord, M. & Farde, L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci. Ther. 17, 97–103 (2011). · DOI · Paper page
  93. Miyamoto, S., Duncan, G. E., Marx, C. E. & Lieberman, J. A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10, 79–104 (2005). · DOI · Paper page
  94. Meltzer, H. Y. & Massey, B. W. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr. Opin. Pharmacol. 11, 59–67 (2011). · DOI · Paper page
  95. Meltzer, H. Y. Pre-clinical pharmacology of atypical antipsychotic drugs: a selective review. Br. J. Psychiatry 168, 23–31 (1996). · DOI · Paper page
  96. O'Tuathaigh, C. M. P., Kirby, B. P., Moran, P. M. & Waddington, J. L. Mutant mouse models: genotype–phenotype relationships to negative symptoms in schizophrenia. Schizophr. Bull. 36, 271–288 (2010). · DOI
  97. Wise, R. A. Forebrain substrates of reward and motivation. J. Comp. Neurol. 493, 115–121 (2005). · DOI · Paper page
  98. Nuechterlein, K. H., Luck, S. J., Lustig, C. & Sarter, M. CNTRICS final task selection: control of attention. Schizophr. Bull. 35, 182–196 (2009). · DOI · Paper page
  99. Bari, A., Dalley, J. W. & Robbins, T. W. The application of the 5-choice serial reaction time task for the assessment of visual attentional processes and impulse control in rats. Nature Protoc. 3, 759–767 (2008). · DOI · Paper page
  100. Joyce, E. et al. Executive dysfunction in first-episode schizophrenia and relationship to duration of untreated psychosis: the West London Study. Br. J. Psychiatry 181, S38–S44 (2002). · DOI · Paper page
  101. Arguello, P. A. & Gogos, J. A. Cognition in mouse models of schizophrenia susceptibility genes. Schizophr. Bull. 36, 289–300 (2010). · DOI · Paper page
  102. Marighetto, A. et al. Comparative effects of the dopaminergic agonists piribedil and bromocriptine in three different memory paradigms in rodents. J. Psychopharmacol. 22, 511–521 (2008). · DOI
  103. Crawley, J. N. et al. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology 132, 107–124 (1997). · DOI · Paper page
  104. Koike, H., Arguello, P. A., Kvajo, M., Karayiorgou, M. & Gogos, J. A. Disc1 is mutated in the 129S6/SvEv strain and modulates working memory in mice. Proc. Natl Acad. Sci. USA 103, 3693–3697 (2006). · DOI · Paper page
  105. Kvajo, M. et al. A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition. Proc. Natl Acad. Sci. USA 105, 7076–7081 (2008). · DOI · Paper page
  106. Hikida, T. et al. Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc. Natl Acad. Sci. USA 104, 14501–14506 (2007). · DOI · Paper page
  107. Niwa, M. et al. Knockdown of DISC1 by in utero gene transfer disturbs postnatal dopaminergic maturation in the frontal cortex and leads to adult behavioral deficits. Neuron 65, 480–489 (2010). · DOI · Paper page
  108. Pletnikov, M. V. et al. Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia. Mol. Psychiatry 13, 173–186 (2008). · DOI · Paper page
  109. Li, W. et al. Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice. Proc. Natl Acad. Sci. USA 104, 18280–18285 (2007). · DOI · Paper page
  110. Kuroda, K. et al. Behavioral alterations associated with targeted disruption of exons 2 and 3 of the Disc1 gene in the mouse. Hum. Mol. Genet. 20, 4666–4683 (2011). · DOI
  111. Stefansson, H. et al. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 71, 877–892 (2002). · DOI · Paper page
  112. O'Tuathaigh, C. M. P. et al. Phenotypic characterization of spatial cognition and social behavior in mice with 'knockout' of the schizophrenia risk gene neuregulin 1. Neuroscience 147, 18–27 (2007). · DOI · Paper page
  113. Golub, M. S., Germann, S. L. & Lloyd, K. C. K. Behavioral characteristics of a nervous system-specific erbB4 knock-out mouse. Behav. Brain Res. 153, 159–170 (2004). · DOI
  114. Barros, C. S. et al. Impaired maturation of dendritic spines without disorganization of cortical cell layers in mice lacking NRG1/ErbB signaling in the central nervous system. Proc. Natl Acad. Sci. USA 106, 4507–4512 (2009). · DOI · Paper page
  115. Siuciak, J. A., McCarthy, S. A., Chapin, D. S. & Martin, A. N. Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology 197, 115–126 (2008). · DOI
  116. Paylor, R. et al. Impaired learning and motor behavior in heterozygous Pafah1b1 (Lis1) mutant mice. Learn. Mem. 6, 521–537 (1999). · DOI · Paper page
  117. Long, J. M. et al. Behavior of mice with mutations in the conserved region deleted in velocardiofacial/DiGeorge syndrome. Neurogenetics 7, 247–257 (2006). · DOI
  118. Paylor, R. et al. Mice deleted for the DiGeorge/velocardiofacial syndrome region show abnormal sensorimotor gating and learning and memory impairments. Hum. Mol. Genet. 10, 2645–2650 (2001). · DOI · Paper page
  119. Drago, J. et al. Altered striatal function in a mutant mouse lacking D1A dopamine receptors. Proc. Natl Acad. Sci. USA 91, 12564–12568 (1994). · DOI · Paper page
  120. Xu, M. et al. Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell 79, 729–742 (1994). · DOI · Paper page
  121. Ralph-Williams, R. J., Lehmann-Masten, V., Otero-Corchon, V., Low, M. J. & Geyer, M. A. Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice. J. Neurosci. 22, 9604–9611 (2002). · DOI · Paper page
  122. Clifford, J. J. et al. Topographical evaluation of behavioural phenotype in a line of mice with targeted gene deletion of the D-2 dopamine receptor. Neuropharmacology 39, 382–390 (2000). · doi:10.1016/s0028-3908(99)00150-1
  123. Kellendonk, C., Simpson, E. H. & Kandel, E. R. Modeling cognitive endophenotypes of schizophrenia in mice. Trends Neurosci. 32, 347–358 (2009). · DOI · Paper page
  124. Babovic, D. et al. Phenotypic characterization of cognition and social behavior in mice with heterozygous versus homozygous deletion of catechol-O-methyltransferase. Neuroscience 155, 1021–1029 (2008). · DOI
  125. Giros, B., Morice, E., Denis, C. & Nosten-Bertrand, M. Phenotypic expression of the targeted null-mutation in the dopamine transporter gene varies as a function of the genetic background. Eur. J. Neurosci. 20, 120–126 (2004). · DOI · Paper page
  126. Morice, E. et al. Parallel loss of hippocampal LTD and cognitive flexibility in a genetic model of hyperdopaminergia. Neuropsychopharmacology 32, 2108–2116 (2007). · DOI
  127. Duncan, G. E. et al. Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav. Brain Res. 153, 507–519 (2004). · DOI · Paper page
  128. Miyamoto, Y. et al. Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor ε1 subunit. J. Neurosci. 21, 750–757 (2001). · DOI · Paper page
  129. Boyce-Rustay, J. M. & Holmes, A. Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice. Neuropsychopharmacology 31, 2405–2414 (2006). · DOI · Paper page
  130. Schmitt, W. B., Deacon, R. M. J., Seeburg, P. H., Rawlins, J. N. P. & Bannerman, D. M. A within-subjects, within-task demonstration of intact spatial reference memory and impaired spatial working memory in glutamate receptor-A-deficient mice. J. Neurosci. 23, 3953–3958 (2003). · DOI · Paper page
  131. Barkus, C. et al. Do GluA1 knockout mice exhibit behavioral abnormalities relevant to the negative or cognitive symptoms of schizophrenia and schizoaffective disorder? Neuropharmacology 62, 1263–1272 (2011). · DOI · Paper page
  132. Wiedholz, L. M. et al. Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and 'schizophrenia-related' behaviors. Mol. Psychiatry 13, 631–640 (2008). · DOI · Paper page
  133. Sagata, N. et al. Comprehensive behavioural study of GluR4 knockout mice: implication in cognitive function. Genes Brain Behav. 9, 899–909 (2010). · DOI
  134. Belforte, J. E. et al. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nature Neurosci. 13, 76–83 (2010). · DOI · Paper page
  135. Tordera, R. M. et al. Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1). Eur. J. Neurosci. 25, 281–290 (2007). · DOI · Paper page
  136. Garcia-Garcia, A. L. et al. Increased vulnerability to depressive-like behavior of mice with decreased expression of VGLUT1. Biol. Psychiatry 66, 275–282 (2009). · DOI
  137. Chen, Y. W. & Lai, W. S. Behavioral phenotyping of V-Akt murine thymoma viral oncogene homolog 1-deficient mice reveals a sex-specific prepulse inhibition deficit in females that can be partially alleviated by glycogen synthase kinase-3 inhibitors but not by antipsychotics. Neuroscience 174, 178–189 (2011). · DOI
  138. Lai, W. S. et al. Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning. Proc. Natl Acad. Sci. USA 103, 16906–16911 (2006). · DOI · Paper page
  139. Cox, M. M. et al. Neurobehavioral abnormalities in the dysbindin-1 mutant, sandy, on a C57BL/56J genetic background. Genes Brain Behav. 8, 390–397 (2009). · DOI · Paper page
  140. Jentsch, J. D. et al. Dysbindin modulates prefrontal cortical glutamatergic circuits and working memory function in mice. Neuropsychopharmacology 34, 2601–2608 (2009). · DOI
  141. Papaleo, F. et al. Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine/D2 pathways. Mol. Psychiatry 17, 85–98 (2012). · DOI · Paper page
  142. Lipina, T. V. et al. Enhanced dopamine function in DISC1-L100P mutant mice: implications for schizophrenia. Genes Brain Behav. 9, 777–789 (2010). · DOI
  143. Hiroi, N. et al. A 200-kb region of human chromosome 22q11.2 confers antipsychotic-responsive behavioral abnormalities in mice. Proc. Natl Acad. Sci. USA 102, 19132–19137 (2005). · DOI
  144. Duncan, G. E., Moy, S. S., Lieberman, J. A. & Koller, B. H. Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction. Pharmacol. Biochem. Behav. 85, 481–491 (2006). · DOI
  145. Duncan, G. E., Moy, S. S., Lieberman, J. A. & Koller, B. H. Effects of haloperidol, clozapine, and quetiapine on sensorimotor gating in a genetic model of reduced NMDA receptor function. Psychopharmacology 184, 190–200 (2006). · DOI
  146. Fradley, R. L. et al. STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating. Behav. Brain Res. 163, 257–264 (2005). · DOI
  147. Brody, S. A., Conquet, F. & Geyer, M. A. Disruption of prepulse inhibition in mice lacking mGluR1. Eur. J. Neurosci. 18, 3361–3366 (2003). · DOI · Paper page
  148. Brody, S. A., Conquet, F. & Geyer, M. A. Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice. Psychopharmacology 172, 187–195 (2004). · DOI

Cited by

See all 183

Metadata

Authors
Pratt, J., Winchester, C., Dawson, N., & Morris, B.
Venue
Nature Reviews Drug Discovery
Published
2012-06-22
Volume
11
Issue
7
Pages
560-579
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W2028510688
Cited by
183
References
40
FWCI
3.13
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.